AMPK modulates the activity of the downstream target PGC-1α, and the resulting reductions in the mRNA and protein expression of PGC-1α (in line with our results in the HCD groups) are indicators of cardiac dysfunction, compromised energy metabolism, and subsequent development of systolic heart failure [66]. This evidence concerns the gene PPARGC1A and heavy chain disease.